Literature DB >> 14722059

Overexpression of CUG triplet repeat-binding protein, CUGBP1, in mice inhibits myogenesis.

Nikolai A Timchenko1, Roma Patel, Polina Iakova, Zong-Jin Cai, Ling Quan, Lubov T Timchenko.   

Abstract

Accumulation of RNA CUG repeats in myotonic dystrophy type 1 (DM1) patients leads to the induction of a CUG-binding protein, CUGBP1, which increases translation of several proteins that are required for myogenesis. In this paper, we examine the role of overexpression of CUGBP1 in DM1 muscle pathology using transgenic mice that overexpress CUGBP1 in skeletal muscle. Our data demonstrate that the elevation of CUGBP1 in skeletal muscle causes overexpression of MEF2A and p21 to levels that are significantly higher than those in skeletal muscle of wild type animals. A similar induction of these proteins is observed in skeletal muscle of DM1 patients with increased levels of CUGBP1. Immunohistological analysis showed that the skeletal muscle from mice overexpressing CUGBP1 is characterized by a developmental delay, muscular dystrophy, and myofiber-type switch: increase of slow/oxidative fibers and the reduction of fast fibers. Examination of molecular mechanisms by which CUGBP1 up-regulates MEF2A shows that CUGBP1 increases translation of MEF2A via direct interaction with GCN repeats located within MEF2A mRNA. Our data suggest that CUGBP1-mediated overexpression of MEF2A and p21 inhibits myogenesis and contributes to the development of muscle deficiency in DM1 patients.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14722059     DOI: 10.1074/jbc.M312923200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  101 in total

Review 1.  Developments in RNA splicing and disease.

Authors:  Michael G Poulos; Ranjan Batra; Konstantinos Charizanis; Maurice S Swanson
Journal:  Cold Spring Harb Perspect Biol       Date:  2011-01-01       Impact factor: 10.005

Review 2.  Epigenetic changes and non-coding expanded repeats.

Authors:  Masayuki Nakamori; Charles Thornton
Journal:  Neurobiol Dis       Date:  2010-02-18       Impact factor: 5.996

3.  (1)H, (15)N and (13)C chemical shift assignments of RNA repeats binding protein -- CUGBP1ab.

Authors:  Kyu-Yeon Jun; Youlin Xia; Xiaogang Han; Hua Zhang; Lubov Timchenko; Maurice S Swanson; Xiaolian Gao
Journal:  J Biomol NMR       Date:  2004-11       Impact factor: 2.835

Review 4.  CELFish ways to modulate mRNA decay.

Authors:  Irina Vlasova-St Louis; Alexa M Dickson; Paul R Bohjanen; Carol J Wilusz
Journal:  Biochim Biophys Acta       Date:  2013-01-15

Review 5.  Misregulation of alternative splicing causes pathogenesis in myotonic dystrophy.

Authors:  N Muge Kuyumcu-Martinez; Thomas A Cooper
Journal:  Prog Mol Subcell Biol       Date:  2006

Review 6.  Pathogenic mechanisms of myotonic dystrophy.

Authors:  Johanna E Lee; Thomas A Cooper
Journal:  Biochem Soc Trans       Date:  2009-12       Impact factor: 5.407

7.  PKC inhibition ameliorates the cardiac phenotype in a mouse model of myotonic dystrophy type 1.

Authors:  Guey-Shin Wang; Muge N Kuyumcu-Martinez; Satyam Sarma; Nitin Mathur; Xander H T Wehrens; Thomas A Cooper
Journal:  J Clin Invest       Date:  2009-11-09       Impact factor: 14.808

8.  Heart-specific overexpression of CUGBP1 reproduces functional and molecular abnormalities of myotonic dystrophy type 1.

Authors:  Misha Koshelev; Satyam Sarma; Roger E Price; Xander H T Wehrens; Thomas A Cooper
Journal:  Hum Mol Genet       Date:  2010-01-05       Impact factor: 6.150

9.  Reduction of the rate of protein translation in patients with myotonic dystrophy 2.

Authors:  Claudia Huichalaf; Benedikt Schoser; Christiane Schneider-Gold; Bingwen Jin; Partha Sarkar; Lubov Timchenko
Journal:  J Neurosci       Date:  2009-07-15       Impact factor: 6.167

Review 10.  CUG-BP, Elav-like family (CELF)-mediated alternative splicing regulation in the brain during health and disease.

Authors:  Andrea N Ladd
Journal:  Mol Cell Neurosci       Date:  2012-12-14       Impact factor: 4.314

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.